Andrew Groves

Studies

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Cancer Pediatrics Sarcoma Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

Phase 1 trial of intrathecal azacitidine and nivolumab in patients with recurrent high-grade glioma

Cancer Pediatrics Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects Female Subjects Male Subjects

This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.

Pharmacogenomic Testing in Children and Young Adults Receiving Care in the Pediatric Hematology/Oncology Clinic at the University of Iowa

Cancer Pediatrics Pediatric Subjects Adult Subjects Female Subjects Male Subjects

Attention Site Visitor

Studies

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Phase 1 trial of intrathecal azacitidine and nivolumab in patients with recurrent high-grade glioma

Pharmacogenomic Testing in Children and Young Adults Receiving Care in the Pediatric Hematology/Oncology Clinic at the University of Iowa